Vyvanse

Takeda Pharmaceuticals America, Inc.🇺🇸 United States

FDA Page

Effective Date: Apr 30, 2026
Approval ID: 704e4378-ca83-445c-8b45-3cfa51c1ecad
Products: 13 registered
Version: 81

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use VYVANSE safely and effectively. See full prescribing information for VYVANSE. VYVANSE (lisdexamfetamine dimesylate) capsules, for oral use, CII VYVANSE (lisdexamfetamine dimesylate) chewable tablets, for oral use, CII Initial U.S. Approval: 2007

Quick Stats

Total Products13

Labelers2

Label Sections33

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.